BioCentury | May 20, 2019
Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Oct 10, 2016
Clinical News

Sustained-release travoprost: Phase III started

Ocular began a double-blind, vehicle-controlled, U.S. Phase III trial to evaluate OTX-XP placed within the canaliculus in about 550 patients. Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Sustained-release travoprost ( OTX-TP ) Business: Ophthalmic Molecular target: NA...
BioCentury | Feb 18, 2016
Clinical News

Ocular Therapeutix rises on OTX-TP update

Ocular Therapeutix Inc. (NASDAQ:OCUL) jumped $2.41 (39%) to $8.67 on Wednesday after it announced plans for two Phase III placebo-controlled trials of OTX-TP to treat glaucoma or ocular hypertension. The company said that based on...
BioCentury | Nov 2, 2015
Clinical News

Sustained-release travoprost: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 73 patients showed that 0.36 mg OTX-TP reduced IOP from baseline to day 60 by 4.8 mmHg vs. 6.4 mmHg for twice-daily timolol eye drops....
BioCentury | Dec 15, 2014
Clinical News

Sustained Release Travoprost: Phase IIb started

Ocular Therapeutix began a double-blind, U.S. Phase IIb trial to compare a single dose of 0.36 mg Sustained Release Travoprost vs. twice-daily timolol eye drops in about 80 patients. Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass....
BioCentury | Jul 21, 2014
Emerging Company Profile

Envisia: Ophthalmic nanotechnology

...expects for its products, or they are not bioerodable. In glaucoma, Ocular Therapeutix Inc. has OTX-TP1...
BioCentury | Jan 29, 2013
Financial News

Ocular raises $23.8M in series D extension

Ocular Therapeutix Inc. (Bedford, Mass.) raised $23.8 million in an extension of a series D round, bringing the total raised in the round to $37.8 million. All of the company's existing institutional investors participated, including...
BioCentury | Nov 5, 2012
Clinical News

Travoprost-loaded punctum plug: Phase II data

...2 months after the company said it showed proof-of-concept (POC) in a feasibility trial with OTX-TP1...
...Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Xalatan. Ocular Therapeutix Inc. , Bedford, Mass. Product: Travoprost-loaded punctum plug...
BioCentury | Oct 31, 2012
Clinical News

Ocular reports Phase II glaucoma data for travoprost plug

Ocular Therapeutix Inc. (Bedford, Mass.) reported top-line data from a Phase II trial to treat glaucoma showing that OTX-TP2 led to a reduction in mean intraocular pressure (IOP) of 6.8 mmHg from baseline to day...
Items per page:
1 - 10 of 13